Indel Therapeutics Inc.

Indel Therapeutics Inc.

September 11, 2012 09:00 ET

Indel Therapeutics Named Industry Partner for New Genomics Research Project

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 11, 2012) - Indel Therapeutics Inc., a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance, announced today that it is the industry partner for a new genomics-based research project entitled, "Combating drug-resistant pathogens". The project is focused on identifying new inhibitors for drug targets that will lead to the creation of novel classes of antimicrobials against Gram negative bacteria and biodefense agents.

As part of this research project, Genome BC awarded funding to Dr. Neil Reiner of the University of British Columbia, the Company's scientific founder and Chief Scientific Officer, and Fiona Brinkman of Simon Fraser University, through its peer-reviewed Proof-of-Concept program. Drs. Reiner and Brinkman, along with industry partner Indel Therapeutics, will work to identify novel drug targets and therapeutics for antibiotic-resistant nosocomial pathogens (hospital-acquired infections) that address the ongoing issue of multidrug-resistant (MDR) bacterial pathogens.

"We could not be more pleased that Genome BC recognizes both the importance and potential of the Indel Antimicrobial Targeting Approach," said Dr. Neil Reiner. "This funding will help identify novel antibiotics to address the global crisis of multidrug-resistant Gram negative infections, an area where there are virtually no new drugs in development."

The Proof-of-Concept program provides funding to help researchers move their work forward from the lab to the market. It fosters the development of novel products and services to the point that they are ready for industry partners like Indel Therapeutics.

"The Proof-of-Concept program provides a valuable opportunity for receptor engagement, in particular industry. This program compels the research community to work hand in hand with end users," says Dr. Alan Winter, President and CEO of Genome BC. "Genome BC is committed to fulfilling our mandate of facilitating the advancement of genomics based discoveries from innovation through to practical applications."

About Indel Therapeutics

Indel Therapeutics Inc. is a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel's paradigm-changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases, which has the potential to provide an advantage against drug resistance. For more information, please visit

About Genome British Columbia

Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast, and manages a cumulative portfolio of over $550M in research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries, agriculture, environment, bioenergy, mining and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada.

Contact Information